Objectives and methods With 432 513 samples from UK Biobank dataset, multivariable linear/logistic regression were used to estimate the relationship between psoriasis/psoriatic arthritis (PsA) and estimated bone mineral density (eBMD)/osteoporosis, controlling for potential confounders. Here, confounders were set in three ways: model0 (including age, height, weight, smoking and drinking), model1 (model0 +regular physical activity) and model2 (model1 +medication treatments). The eBMD was derived from heel ultrasound measurement. And 4904 patients with psoriasis and 847 patients with PsA were included in final analysis. Mendelian randomisation (MR) approach was used to evaluate the causal effect between them.
Results Lower eBMD were observed in patients with PsA than in controls in both model0 (β-coefficient=−0.014, p=0.0006) and model1 (β-coefficient=−0.013, p=0.002); however, the association disappeared when conditioning on treatment with methotrexate or ciclosporin (model2) (β-coefficient=−0.005, p=0.28), mediation analysis showed that 63% of the intermediary effect on eBMD was mediated by medication treatment (p<2E-16). Patients with psoriasis without arthritis showed no difference of eBMD compared with controls. Similarly, the significance of higher risk of osteopenia in patients with PsA (OR=1.27, p=0.002 in model0) could be eliminated by conditioning on medication treatment (p=0.244 in model2). Psoriasis without arthritis was not related to osteopenia and osteoporosis. The weighted Genetic Risk Score analysis found that genetically determined psoriasis/PsA were not associated with eBMD (p=0.24 and p=0.88). Finally, MR analysis showed that psoriasis/PsA had no causal effect on eBMD, osteoporosis and fracture.
Conclusions The effect of PsA on osteoporosis was secondary (eg, medication) but not causal. Under this hypothesis, psoriasis without arthritis was not a risk factor for osteoporosis.
- arthritis, psoriatic
- bone density
Statistics from Altmetric.com
Handling editor Josef S Smolen
Contributors H-FZ conceived and designed the experiments. JX conducted the experiments and analysed the data. JTE, PES, LCT and RPN provided the summary data and critically reviewed the manuscript. BW, S-YX, Y-PZ, K-QL, M-CQ, W-YB, X-WZ, P-KC, P-PZ, S-RG, P-LG, H-QY, KM and Y-TL assisted in the data preparation, cleaning and analysis. Z-MYe, Z-MYing, BH, J-QZ, LX, Z-HY provided comprehensive advices on the clinical explanation of the results and critically reviewed the manuscript. H-FZ supervised the study. JX wrote the manuscript. All authors have read and approved the final manuscript.
Funding This work was supported by the Zhejiang Provincial Natural Science Foundation for Distinguished Young Scholars of China (LR17H070001) and by the National Natural Science Foundation of China (81871831).
Competing interests None declared.
Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.
Patient consent for publication Not required.
Ethics approval All individuals provided written informed consent. North West Multi-centre Research Ethics Committee approved the UK Biobank ethical application.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.